Stockreport

Homology Medicines Presents Details of Optimized HMI-103 Nuclease-Free Gene Editing Candidate Featuring Integrated Liver-Specific Promoter to Maximize Long-Term Expression

Homology Medicines, Inc.  (FIXX) 
Last homology medicines, inc. earnings: 3/12 04:10 pm Check Earnings Report
PDF - Additional Data at ASGCT Annual Meeting Demonstrate Precision of HR-Based Approach with Genome-Wide Integration Assays Confirming On-Target Editing and No Off-Target E [Read more]